AnaptysBio, Inc. operates as a clinical-stage biotechnology firm, primarily focused on the development of novel antibody product candidates. Its pipeline prominently features therapeutic agents such as ANB030 and Imsidolimab. The company also utilizes a proprietary SHM platform, which biologically replicates the human immune system's natural process of somatic hypermutation.